Limaca Medical was featured in the latest Innovation Supplement of CUTTING EDGE magazine, a special project on Haaretz.com under “Haaretz Labels”.
Limaca Medical was featured in the latest Innovation Supplement of CUTTING EDGE magazine, a special project on Haaretz.com under “Haaretz Labels”.
This significant milestone further strengthens Limaca’s operational and quality infrastructure and joins the company’s FDA clearance, reinforcing our commitment to the highest standards of quality, safety, and regulatory excellence.
Dr. Irit Yaniv is a highly respected leader in the MedTech and innovation ecosystem, with more than 25 years of experience spanning executive management, venture capital, and global business development.
Official commercial availability in the United States, supported by FDA clearance, Breakthrough designation and CMS TPT payment.
Regional Medical Center (Anniston, AL) performed the first Precision-GI™ cases in Alabama.
Funding awarded for transfer to manufacturing, supporting cost reduction and scale-up to meet U.S. demand.
Four successful Precision-GI™ procedures completed by Dr. Isaac Raijman with excellent core-quality results.
Additional patents allowed in Europe and Japan, expanding the company’s IP footprint.
Logistics expanded to freight shipments to support growing commercial activity.
Commercialization is supported by Limaca’s clinical trials, operational capabilities, FDA clearance, and CMS Transitional Pass-Through (TPT) Payment award.
Clinical study enrollment completed in Ecuador with outstanding sample quality and efficiency.
TPT status granted, expanding patient access and supporting hospital adoption
Limaca Medical announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”)….
Limaca Medical and HekaBio K.K. announced today that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca’s Precision-GI™ Endoscopic Biopsy Device in Japan…
Limaca Medical announced today that its Precision-GI™ Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”).
Limaca Medical, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies…….